Errata - English

Line 14 of Analysis in Content of Total Phenols: Change
C_S = concentration of the relevant analyte in the corresponding Standard solution
C_U = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
C_S = concentration of the relevant analyte in the corresponding Standard solution (mg/mL)
C_U = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)
AND
Line 20 of Analysis in Content of Dodecatetraenoic Acid Isobutylamides: Change
C_U = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:
C_U = concentration of Powdered Echinacea purpurea Extract in the Sample solution (mg/mL)

Line 7 of Analysis: Change
R_U = peak area ratio of ibuprofen to valerophenone from the Sample solution
R_S = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
R_U = peak area ratio of ibuprofen related compound C to valerophenone from the Sample solution
R_S = peak area ratio of ibuprofen related compound C to valerophenone from the Standard solution

Line 6 of Analysis: Change
Result = (A_U/A_S) × (C_S/C_U) × P × 100
to:
Result = (A_U/A_S) × (C_S/C_U) × P × F × 100
AND
After P in definition list: Add
F = conversion factor, 0.001 mg/μg

Line 2 of USP Valsartan Related Compound A RS: Change
(R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine.
AND
Line 2 of USP Valsartan Related Compound B RS: Change
(S)-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
AND
Line 2 of USP Valsartan Related Compound C RS: Change
(S)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.

Line 1 of System suitability solution: Change
Transfer 2.0 mL of System suitability stock solution A and System suitability stock solution B
to:
Transfer 2.0 mL of each System suitability stock solution A and System suitability stock solution B
AND
Line 2 of Standard solution A: Change
Mix 5.0 of the solution
to:
Mix 5.0 mL of the solution

Line 1 of Standard solution: Change
0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
to:
0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium
AND
Line 8 of Analysis: Change
C_S = concentration of ciprofloxacin in the Standard solution (mg/mL)
to:
C_S = concentration of ciprofloxacin hydrochloride in the Standard solution (mg/mL)

Line 6 of Analysis: Change
Result = (R_U/R_S) × (C_S/C_U) × 100
to:
Result = (R_U/R_S) × (C_S/C_U) × (M_r1/M_r2) × 100
AND
After C_U in definition list: Add
M_r1 = molecular weight of codeine phosphate hemihydrate, 406.37
M_r2 = molecular weight of anhydrous codeine phosphate, 397.37

Line 5 of Magnesium stock solution: Change
Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg)
to:
Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of magnesium (Mg)

Row 13 of Column 1 of Table 2: Change
3-Epimer^m
to:
3R-Epimer^m
AND
Row 16 of Column 1 of Table 2: Change
5-Epimer^p
to:
5R-Epimer^p
AND
Row 17 of Column 1 of Table 2: Change
Valine urea analog^q
to:
Diacyl valine urea^q